Toxicogenomics

Handbook of Pharmaceutical Biotechnology

Volumn , Issue , 2006, Pages 229-251

  Cunningham, Mary Jane ^a   Shah, Mrinal ^a  

^a HOUSTON ADVANCED RESEARCH CENTER   (United States)

Author keywords

Nanotechnology field; Proteomics in toxicology; Toxicogenomics

Indexed keywords

EID: 84889764090     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470117118.ch3a     Document Type: Chapter

References (175)

1. Vojta P J, Kazmer V P, Kier L D (2001/2002). Toxicogenomics: Insights into the present and future. Drug Disc. World. 3:18-22.
2. Farr S, Dunn R T (1999). Concise review: Gene expression applied to toxicology. Toxicol. Sci. 50:1-9.
3. Nuwaysir E F, Bittner M, Trent J, et al. (1999). Microarrays and toxicology: The advent of toxicogenomics. Molecular Carcinogen. 24:153-159.
4. Cunningham M J, Zacharewski T, Somogyi R, et al. (2002). Two-stepping through toxicogenomics: A basic primer. Toxicol. Sci. 66:1.
5. Nadadur S, Cunningham M J (2006). Predictive power of novel technologies (cells to "Omics"): Promises, pitfalls and potential applications. Toxicol. Sci. 90:1.
6. Mohrenweiser H W (2004). Genetic variation and exposure related risk estimation: will toxicology enter a new era? DNA repair and cancer as a paradigm. Toxicol. Pathol. 32:(1):136-145.
7. Cunningham M J (2000). Genomics and proteomics: the new millennium of drug development and discovery. Journal of Pharmacol. Toxicolog. Methods. 44:291-300.
8. Page M J, Moyses C, Cunningham M J, et al. (2003). Proteomics. EXS. 93:19-30.
9. Nicholson J K, Lindon J C, Holmes E (1999). "Metabonomics": Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 29:1181-1189.
10. Sengupta L K, Sengupta S, Sarkar M (2002). Pharmacogenetic applications of the post genomic era. Current Pharmac. Biotechnol. 3:141-150.
11. Regnstrom K, Burgess D J (2005). Pharmacogenomics and its potential impact on drug and formulation development. Critical Rev. Therap. Drug Carrier Sys. 22:465-492.
12. Severino G, Del Zompo M (2004). Adverse drug reactions: Role of pharmacogenomics. Pharmacological Res. 49:363-373.
13. Cunningham M J, Dat D D (2005). Microarrays-Fabricating, Fuchs J and Podda M, (ed.), Marcel Dekker, Encyclopedia of Diagnostic Genomics and Proteomics. New York, pp. 819-823.
14. Lee K M, Kim J H, Kang D (2005). Design issues in toxicogenomics using DNA microarray experiment. Toxicol. Appl. Pharm. 207:S200-S208.
15. Yauk C L, Berndt M L, Williams A, et al. (2004). Comprehensive comparison of six microarray technologies. Nucleic Acids Res. 32:e124.
16. Brazma A, Hingamp P, Quackenbush J, et al. (2001). Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nature Genetics. 29:365-371.
17. Microarray Gene Expression Data (MGED) Society. A MIAME for Toxicogenomics-MIAME/Tox, Based on Tox 1.1., Draft Publication, August, 2003. Available: http:// www.mged.org.
18. Mattes W B, Pettit S D, Sansone S A, et al. (2004). Database development in toxicogenomics: Issues and efforts. Environ. Health Persp. 112:495-505.
19. Novoradovskaya N, Whitfield M L, Basehore L S, et al. (2004). Universal reference RNA as a standard for microarray experiments. BMC Genomics. 5:20.
20. Shih J H, Michalowska A M, Dobbin K, et al. (2004). Effects of pooling mRNA in microarray class comparisons. Bioinformatics. 20:3318-3325.
21. Zhang S D, Gant T W (2005). Effect of pooling samples on the efficiency of comparative studies using microarrays. Bioinformatics. 21:4378-4383.
22. Glass A, Henning J, Karopka T, et al. (2005). Representation of individual gene expression in completely pooled mRNA samples. Biosci. Biotechnol. Biochem. 69:1098-1103.
23. Kendziorski C M, Zhang Y, Lan H, et al. (2003). The efficiency of pooling mRNA in microarray experiments. Biostatistics. 4:465-477.
24. Jolly R A, Goldstein K M, Wei T, et al. (2005). Pooling samples within micro array studies: A comparative analysis of rat liver transcription response to prototypical toxicants. Physiol. Genomics. 22:346-355.
25. Peng X, Wood C L, Blalock E M, et al. (2003). Statisical implications of pooling RNA samples for microarray experiments. BMC Bioinformatics. 4:26.
26. Khrapko K R, Lysov Y P, Khorlyn A A, et al. (1989). An oligonucleotide hybridization approach to DNA sequencing. FEBS Lett. 256:118-122.
27. Southern E M, Maskos U, Elder J K (1992). Analyzing and comparing nucleic acid sequences by hybridization to arrays of oligonucleotides: Evaluation using experimental models. Genomics. 13:1008-1017.
28. Maskos U, Southern E M (1992). Oligonucleotide hybridisations on glass supports: A novel linker for oligonucleotide synthesis and hybridisation properties of oligonucleotides synthesised in situ. Nucleic Acids Res. 20:1679-1684.
29. Drmanac R, Drmanac S, Strezoska Z, et al. (1993). DNA sequence determination by hybridization: A strategy for efficient large-scale sequencing. Science. 260:1649-1652.
30. Beattie W G, Meng L, Turner S L, et al. (1995). Hybridization of DNA targets to glass-tethered oligonucleotide probes. Molecular Biotechnol. 4:213-225.
31. Augenlicht L H, Wahrman M Z, Halsey H, et al. (1987). Expression of cloned sequences in biopsies of human colonic tissue and in colonic carcinoma cells induced to differentiate in vitro. Cancer Res. 47:6017-6021.
32. Gray N S, Wodicka L, Thunnissen A M W H, et al. (1998). Exploiting chemical libraries, structure and genomics in the search for kinase inhibitors. Science. 281:533-538.
33. Braxton S, Bedilion T (1998). The integration of microarray information in the drug development process. Curr. Opin. Biotech. 9:643-649.
34. Karpf A R, Peterson P W, Rawlins J T, et al. (1999). Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc. of the National Academy of Sciences USA. 96:14007-14012.
35. Cunningham M J, Zweiger G, Bailey D, et al. (1998). Application of a genome-based screen. Archives of Pharmacol. 358:R564.
36. Cunningham M J, Liang S, Fuhrman S, et al. (2000). Gene expression micro array data analysis for toxicity profiling. Annals of the New York Acad. Sci. 919:52-67.
37. Fuhrman S, Cunningham M J, Wen X, et al. (2000). The application of Shannon entropy in the identification of putative drug targets. BioSys. 55:5-14.
38. Fuhrman S, Cunningham M J, Liang S, et al. (2000). Making sense of large-scale gene expression data with simple computational techniques. Amer. Biotechnol. Lab. 18:68-70.
39. Burczynski M E, McMillian M, Ciervo J, et al. (2000). Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol. Sci. 58:399-415.
40. Waring J F, Jolly R A, Ciurlionis R, et al. (2001). Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol. Appl. Pharm. 175:28-42.
41. Thomas R S, Rank D R, Penn S G, et al. (2001). Identification of toxicologically predictive gene sets using cDNA microarrays. Molec. Pharmacol. 60:1189-1194.
42. Hamadeh H K, Bushel P R, Jayadev S, et al. (2002). Gene expression analysis reveals chemical-specific profiles. Toxicol. Sci. 67:219-231.
43. Hamadeh H K, Bushel P R, Jayadev S, et al. (2002). Prediction of compound signature using high density gene expression profiling. Toxicol. Sci. 67:232-240.
44. de Longueville F, Atienzar F A, Marcq L, et al. (2003). Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytes. Toxicol. Sci. 75:378-392.
45. Ishida S, Shigemoto-Mogami Y, Kagechika H, et al. (2003). Clinically potential subclasses of retinoid synergists revealed by gene expression profiling. Molec. Cancer Therapeutics. 2:49-58.
46. Kier L D, Neft R, Tang L, et al. (2004). Applications of microarrays with toxicologically relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro. Mutation Res. 549:101-113.
47. Hu T, Gibson D P, Carr G J, et al. (2004). Identification of a gene expression profile that discriminates indirect-acting genotoxins from direct-acting genotoxins. Mutation Res. 549:5-27.
48. McMillian M, Nie A Y, Parker J B, et al. (2004). A gene expression signature for oxidant stress/reactive metabolites in rat liver. Biochem. Pharmacol. 68:2249-2261.
49. Nadadur S S, Schladweiler M C J, Kodavanti U P (2000). A pulmonary rat gene array for screening altered expression profiles in air pollutant-induced lung injury. Inhalation Toxicol. 12:1239-1254.
50. Bae D S, Hanneman W H, Yang R S H, et al. (2002). Characterization of gene expression changes associated with MNNG, arsenic, or metal mixture treatment in human keratinocytes: Application of cDNA microarray technology. Environ. Health Persp. 110(Suppl. 6):931-941.
51. Wang D Y, McKague B, Liss S N, et al. (2004). Gene expression profiles for detecting and distinguishing potential endocrine-disrupting compounds in environmental samples. Environ. Sci. Technol. 38:6396-6406.
52. Jessen B A, Mullins J S, de Peyster A, et al. (2003). Assessment of hepatocytes and liver slices as in vitro test systems to predict in vivo gene expression. Toxicol. Sci. 75:208-222.
53. Boess F, Kamber M, Romer S, et al. (2003). Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: Possible implications for toxicogenomics use of in vitro systems. Toxicol. Sci. 73:386-402.
54. Konu O, Kane J K, Barrett T, et al. (2001). Region-specific transcriptional response to chronic nicotine in rat brain. Brain Res. 909:194-203.
55. Hamadeh H K, Knight B L, Haugen A C, et al. (2002). Methapyrilene toxicity: Anchorage of pathologic observations to gene expression alterations. Toxicol. Pathol. 30:470-482.
56. Kriete A, Anderson M K, Love B, et al. (2003). Combined histomorphometric and gene-expression profiling applied to toxicology. Genome Biol. 4:R32.1-R32.9.
57. Sadlier D M, Connolly S B, Kieran N E, et al. (2004). Sequential extracellular matrixfocused and baited-global cluster analysis of serial transcriptomic profiles identifies candidate modulators of renal tubulointerstitial fibrosis in murine adriamycin-induced nephropathy. J. Biolog. Chem. 279:29670-29680.
58. Kisby G E, Standley M, Lu X, et al. (2005). Molecular networks perturbed in a developmental animal model of brain injury. Neurobiol. Dis. 19:108-118.
59. Luo W, Fan W, Xie H, et al. (2005). Phenotypic anchoring of global gene expression profiles induced by N-hydroxy-4-acetylaminobiphenyl and benzo[a]pyrene diol epoxide reveals correlations between expression profiles and mechanism of toxicity. Chem. Res. Toxicol. 18:619-629.
60. Boverhof D R, Burgoon L D, Tashiro C, et al. (2005). Temporal and dose-dependent hepatic gene expression patterns in mice provide new insights into TCDD-mediated hepatotoxicity. Toxicol. Sci. 85:1048-1063.
61. Huang Q, Jin X, Gaillard E T, et al. (2004). Gene expression profiling reveals multiple toxicity endpoints induced by hepatotoxicants. Mutation Res. 549:147-168.
62. Patel S K, Ma N, Monks T J, et al. (2003). Changes in gene expression during chemical- induced nephrocarcinogenicity in the Eker rat. Molecular Carcinogen. 38:141-154.
63. Heinloth A N, Irwin R D, Boorman G A, et al. (2004). Gene expression profiling of rat livers reveals indicators of potential adverse effects. Toxicol. Sci. 80:193-202.
64. Ogawa K, Asamoto M, Suzuki S, et al. (2005). Downregulation of apoptosis revealed by laser microdissection and cDNA microarray analysis of related genes in rat liver preneoplastic lesions. Medical Molec. Morphol. 38:23-29.
65. Chung C Y, Seo H, Sonntag K C, et al. (2005). Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Human Molec. Genetics. 14:1709-1725.
66. Lefebvre d'Hellencourt C, Harry G J (2005). Molecular profiles of mRNA levels in laser capture microdissected murine hippocampal regions differentially responsive to TMT-induced cell death. J. Neurochem. 93:206-220.
67. Zhou T, Jia X, Chapin R E, et al. (2004). Cadmium at a non-toxic dose alters gene expression in mouse testes. Toxicol. Lett. 154:191-200.
68. Anderson N L, Anderson N G (1998). Proteome and proteomics: New technologies, new concepts, and new words. Electrophoresis. 19:1853-1861.
69. Yarmush M L, Jayaraman A (2002). Advances in proteomic technologies. Ann. Rev. Biomed. Engin. 4:349-373.
70. Anderson N L, Anderson N G (1991). A two-dimensional gel database of human plasma proteins. Electrophoresis. 12:883-906.
71. Kennedy S (2002). The role of proteomics in toxicology: Identification of biomarkers of toxicity by protein expression analysis. Biomarkers. 7:269-290.
72. Kennedy S (2001). Proteomic profiling from human samples: The body fluid alternative. Toxicol. Lett. 120:379-384.
73. Fountoulakis M (2001). Proteomics: Current technologies and applications in neurological disorders and toxicology. Amino Acids. 21:363-381.
74. Fountoulakis M, Berndt P, Boelsterli U A, et al. (2000). Two-dimensional database of mouse liver proteins: Changes in hepatic protein levels following treatment with acetaminophen or its nontoxic regioisomer 3-acetamidophenol. Electrophoresis. 21:2148-2161.
75. Ruepp S U, Tonge R P, Shaw J, et al. (2002). Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol. Sci. 65:135-150.
76. O'Farrell P H (1975). High resolution two-dimensional electrophoresis of proteins. J. Biolog. Chem. 250:4007-4021.
77. McGregor E, Dunn M J (2003). Proteomics of heart disease. Human Molec. Genetics. 12:R135-R144.
78. James P (2001). Protein expression analysis: From "tip of the iceberg" to a global method. Disease Markers. 17:235-246.
79. Anderson N L, Esquer-Blasco R, Richardson F, et al. (1996). The effects of peroxisome proliferators on protein abundances in mouse liver. Toxicol. Appl. Pharm. 137:75-89.
80. Bruno M K, Khairallah E A, Cohen S D (1998). Inhibition of protein phosphatase activity and changes in protein phosphorylation following acetaminophen exposure in cultured mouse hepatocytes. Toxicol. Appl. Pharm. 153:119-132.
81. Witzmann F A, Carpenter R L, Ritchie G D, et al. (2000). Toxicity of chemical mixtures: Proteomic analysis of persisting liver and kidney protein alterations induced by repeated exposure of rats to JP-8 jet fuel vapor. Electrophoresis. 21:2138-2147.
82. Steiner S, Aicher L, Raymackers J, et al. (1996). Cyclosporine A decreases the protein level of the calcium-binding protein calbindin-D 28kDa in rat kidney. Biochem. Pharmacol. 51:253-258.
83. Bandara L R, Kelly M D, Lock E A, et al. (2003). A correlation between a proteomic evaluation and conventional measurements in the assessment of renal proximal tubular toxicity. Toxicol. Sci. 73:195-206.
84. Wetmore B A, Merrick B A (2004). Toxicoproteomics: Proteomics applied to toxicology and pathology. Toxicol. Pathol. 32:619-642.
85. Anderson N L, Taylor J, Hofmann H-P, et al. (1996). Simultaneous measurement of hundreds of liver proteins: Application in assessment of liver function. Toxicol. Pathol. 24:72-76.
86. Thome-Kromer B, Bonk I, Klatt M, et al. (2003). Toward the identification of liver toxicity markers: A proteome study in human cell culture and rats. Proteomics. 3:1835-1862.
87. MacBeath G, Schreiber S L (2000). Printing proteins as microarrays for high-throughput function determination. Science. 289:1760-1763.
88. Zhu H, Bilgin M, Bangham R, et al. (2001). Global analysis of protein activities using proteome chips. Science. 293:2101-2105.
89. Petricoin E F, Zoon K C, Kohn E C, et al. (2002). Clinical Proteomics: Translating benchside promise into bedside reality. Nature Rev. Drug Disc. 1:683-695.
90. Petricoin E F, Rajapaske V, Herman E, et al. (2004). Toxicoproteomics: Serum proteomic pattern diagnostics for early detection of drug induced cardiac toxicities and cardioprotection. Toxicol. Pathol. 32:122-130.
91. Kell D B (2002). Metabolomics and machine learning: Explanatory analysis of complex metabolome data using genetic programming to produce simple, robust rules. Molecular Biol. Reports. 29:237-241.
92. Watkins S M, German J B (2002). Toward the implementation of metabolomics assessments of human health and nutrition. Curr. Opin. Biotech. 13:512-516.
93. Griffin J L, Bollard M E (2004). Metabonomics: Its potential as a tool in toxicology for safety assessment and data integration. Curr. Drug Metabol. 5:389-398.
94. Robertson D G (2005). Metabonomics in toxicology: A review. Toxicol. Sci. 85:809-822.
95. Adams A (2003). Metabolomics: Small molecule "Omics". The Scientist. 17:38-40.
96. Griffin J L (2004). Metabolic profiles to define the genome: Can we hear the phenotypes? Philos. T. Roy. Soc. B. 35, 857-871.
97. Weckwerth W, Morganthal K (2005). Metabolomics: From pattern recognition to biological interpretation. Drug Disc. Today. 10:1551-1558.
98. Keun H C (2006). Metabonomic modeling of drug toxicity. Pharmacol. Therap. 109:92-106.
99. Reo N V (2002). NMR-based metabolomics. Drug and Chem. Toxicol. 25:375-382.
100. Nicholson J K, Buckingham M J, Sadler P J (1983). High resolution 1H NMR studies of vertebrate blood and plasma. Biochem. J. 211:605-615.
101. Nicholson J K, Timbrell J A, Sadler P J (1985). Proton NMR spectra of urine as indicators of renal damage: Mercury-induced nephrotoxicity in rats. Molec. Pharmacol. 27:644-651.
102. Gartland K P R, Beddell C R, Lindon J C, et al. (1991). Application of pattern recognition methods to the analysis and classification of toxicological data derived from proton nuclear magnetic resonance spectroscopy of urine. Molec. Pharmacol. 39:629-642.
103. Holmes E, Nicholls A W, Lindon J C, et al. (1998). Development of a model for classification of toxin-induced lesions using 1H NMR spectroscopy of urine combined with pattern recognition. NMR in Biomedicine. 11:235-244.
104. Nicholson J K, Higham D P, Timbrell J A, et al. (1989). Quantitative high resolution 1H NMR urinalysis studies on the biochemical effects of cadmium in the rat. Molec. Pharmacol. 36:398-404.
105. Robertson D G, Reily M D, Sigler R E, et al. (2000). Metabonomics: Evaluation of nuclear magnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. Toxicol. Sci. 57:326-337.
106. Beckwith-Hall B M, Nicholson J K, Nicholls A W, et al. (1998). Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins. Chem. Res. Toxicol. 11:260-272.
107. Moka D, Vorreuther R, Schicha H, et al. (1998). Biochemical classification of kidney carcinoma biopsy samples using magic-angle-spinning 1H nuclear magnetic resonance spectroscopy. J. Pharmac. Biomed. Anal. 17:125-132.
108. Waters N J, Holmes E, Williams A, et al. (2001). NMR and pattern recognition studies on the time-related metabolic effects of α-naphthylisothiocyanate on liver, urine, and plasma in the rat: An integrative metabonomic approach. Chem. Res. Toxicol. 14:1401-1412.
109. Coen M, Lenz E M, Nicholson J K, et al. (2003). An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy. Chem. Res. Toxicol. 16:295-303.
110. Car B D, Robertson R T (1999). Commentary: Discovery toxicology-a nascent science. Toxicol. Pathol. 27:481-483.
111. Lindon J C, Nicholson J K, Holmes E, et al. (2003). Contemporary issues in toxicology: The role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol. Appl. Pharm. 187:137-146.
112. Lindon J C (2005). The consortium for metabonomic toxicology (COMET): Aims, activities and achievements. Pharmacogenomics. 6:691-699.
113. Goldstein D B, Tate S K, Sisodiya S M (2003). Pharmacogenetics goes genomic. Nature Rev. Genetics. 4:937-947.
114. Shastry B S (2005). Genetic diversity and new therapeutic concepts. J. Human Genetics. 50:321-328.
115. Kalow W (1956). Familial incidence of low pseudocholinesterase level. Lancet. 2:576-577.
116. Carsen P R, Flanagan C L, Iokes C E (1956). Enzymatic deficiency in primaquinesensitive erythrocytes. Science. 124:484-485.
117. Kalow W, Staron N (1957). On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers. Canadian J. Biochem. Physiol. 35:1305-1320.
118. Motulsky A G (1957). Drug reactions, enzymes and biochemical genetics. J. Amer. Med. Assoc. 165:835-837.
119. Kalow W (1997). Pharmacogenetics in biological perspective. Pharmacol. Rev. 49:369-379.
120. Ingelman-Sundberg M, Rodriguez-Antona C (2005). Pharmacogenetics of drugmetabolizing enzymes: Implications for a safer and more effective drug therapy. Philos. T. Roy. Soc. B. 360:1563-1570.
121. Danielson P B (2002). The cytochrome P450 superfamily: Biochemistry, evolution and drug metabolism in humans. Curr. Drug Metabol. 3:561-597.
122. Cascorbi I (2006). Genetic basis of toxic reactions to drugs and chemicals. Toxicol. Lett. 162:16-28.
123. Ingelman-Sundberg M (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5:6-13.
124. Barham H M, Lennard M S, Tucker G T (1994). An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: Relevance to its use as a model of the CYP2D6 poor metaboliser phenotype. Biochem. Pharmacol. 47: 1295-1307.
125. Vorhees C V, Reed T M, Schilling M A, et al. (1998). CYP2D1 polymorphism in methamphetamine-treated rats: Genetic differences in neonatal mortality and effects on spatial learning and acoustic startle. Neurotoxicol. Teratol. 20:265-273.
126. Paulson S K, Zhang J Y, Jessen S M, et al. (2000). Comparison of celecoxib metabolism and excretion in mouse, rabbit, dog, cynomolgus monkey and rhesus monkey. Xenobiotica. 30:731-744.
127. Mise M, Yadera S, Matsuda M, et al. (2004). Polymorphic expression of CYP1A2 leading to interindividual variability in metabolism of a novel benzodiazepine receptor partial inverse agonist in dogs. Drug Metabol. Dispos. 32:240-245.
128. Kusano K, Seko T, Tanaka S, et al. (1996). Purfication and characterization of Rhesus monkey liver amido hydrolases and their roles in the metabolic polymorphism for E6123, a platelet-activating factor receptor antagonist. Drug Metabol. Dispos. 24:1186-1191.
129. Cronin M T, Fucini R V, Kim S M, et al. (1996). Cystic fibrosis mutation detection by hybridization to light-generated DNA probe arrays. Human Mutation. 7:244-255.
130. Kozal M J, Shah N, Shen N, et al. (1996). Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nature Med. 2:753-759.
131. Hacia J G, Brody L C, Chee M S, et al. (1996). Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis. Nature Genetics. 14:441-447.
132. Kulle B, Schirmer M, Toller M R, et al. (2005). Application of genomewide SNP arrays for detection of simulated susceptibility loci. Human Mutation. 25:557-565.
133. Bao Y P, Huber M, Wei T F, et al. (2005). SNP identification in unamplified human genomic DNA with gold nanoparticle probes. Nucleic Acids Res. 33:e15.
134. Witkamp R F (2005). Genomics and systems biology-how relevant are the developments to veterinary pharmacology, toxicology and therapeutics? J. Veterinary Pharmacol. Therapeut. 28:235-245.
135. Barabasi A L, Oltvai Z N (2004). Network biology: Understanding the cell's functional organization. Nature Rev. Genetics. 5:101-113.
136. Heijne W H, Kienhuis A S, van Ommen B, et al. (2005). Systems toxicology: Applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology. Expert Rev. Proteomics. 2:767-780.
137. Ekins S, Nikolsky Y, Nikolskaya T (2005). Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharmaceut. Sci. 26:202-209.
138. Cunningham M J (2000). Toxicological database mining in the twenty-first century. Toxicol. Sci. 54(1-S):412.
139. Tomita M (2001). Whole-cell simulation: A grand challenge of the 21st century. Trends in Biotechnol. 19:205-210.
140. Cunningham M J, Holt G, Moyes C, et al. (2000). The use of proteomics in molecular toxicology. Toxicol. Sci. 54(1-S):62.
141. Keitt S K, Fagan T F, Marts S A (2004). Understanding sex differences in environmental health: A thought leaders' roundtable. Environ. Health Perspec. 112:604-609.
142. Hogstrand C, Balesaria S, Glover C N (2002). Application of genomics and proteomics for study of the integrated response to zinc exposure in a non-model fish species, the rainbow trout. Compar. Biochem. Physiol. Part B, Biochem. Molec. Biol. 133:523-535.
143. Fountoulakis M, de Vera M C, Crameri F, et al. (2002). Modulation of gene and protein expression by carbon tetrachloride in the rat liver. Toxicol. Applied Pharmacol. 183:71-80.
144. Bro C, Regenberg B, Lagniel G, et al. (2003). Transcriptional, proteomic and metabolic response to lithium in galactose-grown yeast cells. J. Biolog. Chem. 278:32141-32149.
145. Heijne W H M, Stierum R H, Slijper M, et al. (2003). Toxicogenomics of bromobenzene hepatotoxicity: A combined transcriptomics and proteomics approach. Biochem. Pharmacol. 65:857-875.
146. Coen M, Ruepp S U, Lindon J C, et al. (2004). Integrated application of transcriptomics and metabonomics yields new insight into the toxicity due to paracetamol in the mouse. J. Pharmac. Biomed. Anal. 35:93-105.
147. Schnackenberg L, Jones R C, Thyparambil S, et al. (2006). An integrated study of acute effects of valproic acid in the liver using metabonomics, proteomics, and transcriptomics platforms. OMICS: A J. Integ. Boil. 10:1-14.
148. Kleno T G, Kiehr B, Baunsgaard D, et al. (2004). Combination of "omics" data to investigate the mechanism(s) of hydrazine-induced hepatotoxicity in rats and to identify potential biomarkers. Biomarkers. 9:116-138.
149. Cunningham M J, Magnuson S R, Falduto M T (2005). Gene expression profiling of nanoscale materials using a systems biology approach. Toxicol. Sci. 84(1-S):9.
150. Monteiro-Riviere N, Cunningham M J (2006). Screening methods for assessing skin toxicity of nanomaterials. Toxicol. Sci. 90(1-S):5.
151. You A J, Jackman R J, Whitesides G M, et al. (1997). A miniaturized arrayed assay format for detecting small molecule-protein interactions in cells. Chem. & Biol. 4:969-975.
152. Kuruvilla F G, Shamji A F, Sternson S M, et al. (2002). Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays. Nature. 416:653-657.
153. Xia Y, Whitesides G M (1998). Soft lithography. Angewandte Chemie (Inter national Edition in English). 37:550-575.
154. Kane R S, Takayama S, Ostuni E, et al. (1999). Patterning proteins and cells using soft lithography. Biomaterials. 20:2363-2376.
155. Ziauddin J, Sabatini D M (2001). Microarrays of cells expressing defined cDNAs. Nature. 411:107-110.
156. Kononen J, Bubendorf L, Kallioniemi A, et al. (1998). Tissue microarrays for highthroughput molecular profiling of tumor specimens. Nature Med. 4:844-847.
157. Moch H, Schraml P, Bubendorf L, et al. (1999). High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Amer. J. Pathol. 154:981-986.
158. Bubendorf L, Kolmer M, Kononen J, et al. (1999). Hormone therapy failure in human prostate cancer: Analysis by complementary DNA and tissue microarrays. J. National Cancer Institute. 91:1758-1764.
159. Matysiak S, Reuthner F, Hoheisel J D (2001). Automating parallel peptide synthesis for the production of PNA library arrays. Biotechniques. 31:896-904.
160. Fritz J, Baller M K, Lang H P, et al. (2000). Translating biomolecular recognition into nanomechanics. Science. 288:316-318.
161. McKendry R, Zhang J, Arntz Y, et al. (2002). Multiple label-free biodetection and quantitative DNA-binding assays on a nanomechanical cantilever array. Proc. of the National Academy of Sciences. 99:9783-9788.
162. Choi J W, Park K W, Lee D B, et al. (2005). Cell immobilization using self-assembled synthetic oligopeptide and its application to biological toxicity detection using surface plasmon resonance. Biosens. and Bioelectron. 20:2300-2305.
163. How S E, Yingyongnarongkul B, Fara M A, et al. (2004). Polyplexes and lipoplexes for mammalian gene delivery: From traditional to microarray screening. Combinat. Chem. & High Throughput Screen. 7:423-430.
164. Piner R D, Zhu J, Xu F, et al. (1999). "Dip-pen" nanolithography. Science. 283:661-663.
165. Park S J, Taton A T, Mirkin C A (2002). Array-based electrical detection of DNA with nanoparticle probes. Science. 295:1503-1506.
166. Taton A T, Mirkin C A, Letsinger R L (2000). Scanometric DNA array detection with nanoparticle probes. Science. 289:1757-1760.
167. Abdelrahim M, Smith R, Safe S (2003). Aryl hydrocarbon receptor gene silencing with small inhibitory RNA differentially modulates Ah-responsiveness in MCF-7 and HepG2 cancer cells. Mol. Pharmacol. 63:1373-1381.
168. Krichevsky A M, King K S, Donahue C P, Khrapko K, Kosik K S (2003). A microRNA array reveals extensive regulation of microRNAs during brain development. RNA 9:1274-1281.
169. Miska E A, Alvarez-Saavedra E, Townsend M, Yoshii A, Sestan N, Rakic P, Constantine-Paton M, Horvitz H R (2004). Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol. 5:R68.
170. Dalmay T (2006). Short RNAs in environmental adaptation. Proc. Biol. Soc. 273:1579-1585.
171. Yang Z, Wu J (2006). Small RNAs and development. Med. Sci. Monit. 12:RA125- RA129.
172. Ying S Y, Chang D C, Miller J D, Lin S L (2006). The microRNA: Overview of the RNA gene that modulates gene function. Methods Mol. Biol. 342:1-18.
173. Downing G J, Battey J F (2004). Technical assessment of the first 20 years of research using mouse embryonic stem cell lines. Stem Cells. 22:1168-1180.
174. Ruhnke M, Ungefroren H, Zehle G, et al. (2003). Long-term culture and differentiation of rat embryonic stem cell-like cells into neuronal, glial, endothelial, and hepatic lineages. Stem Cells. 21:428-436.
175. Bremer S, Hartung T (2004). The use of embryonic stem cells for regulatory developmental toxicity testing in vitro-the current status of test development. Curr. Pharmac. Design. 10:2733-2747.